Photonic bone density spectroscopy market seen growing to $1.73 billion by 2030

The photonic bone density spectroscopy device market is projected to rise from $1.17 billion in 2025 to $1.73 billion by 2030, driven by demand for non-invasive diagnostics and radiation-free imaging. North America led the market in 2025, while Asia-Pacific is expected to grow fastest over the forecast period.

Why it matters: - The market outlook points to faster adoption of safer, non-invasive bone health testing as osteoporosis and other bone disorders become more common. - Growth in photonic bone density spectroscopy could expand access to early detection, routine monitoring and point-of-care diagnostics without ionizing radiation. - The sector is also being shaped by AI, cloud-connected analytics and portable imaging, which could change how bone health is assessed in clinics and remote settings.

What happened: - The Business Research Company projected the photonic bone density spectroscopy device market to grow from $1.17 billion in 2025 to $1.26 billion in 2026. - The report expects the market to reach $1.73 billion by 2030, reflecting an 8.2% CAGR. - The company released the market outlook July 21, 2026, from London. - More information is available through a free sample request. - The full report is also available online.

The details: - Photonic bone density spectroscopy devices use light-based technology to measure bone density and bone quality without ionizing radiation. - The systems are designed for safe, painless and precise evaluation of bone conditions such as osteoporosis. - The devices are used in clinical settings and research environments for preventive care and patient monitoring. - The report said growth through 2026 is being driven by rising osteoporosis cases, demand for non-invasive imaging, advances in optical and photonic technologies, improved diagnostic infrastructure and greater awareness of preventive bone screenings. - The 2030 growth outlook is tied to AI in diagnostic imaging, wider use of radiation-free imaging, and more portable and point-of-care devices. - The report also pointed to precision medicine, early disease detection and cloud-enabled data sharing and analytics as additional tailwinds. - Future product development is expected to include AI-powered photonic bone density analytics for early osteoporosis detection, non-ionizing laser-based multispectral bone assessment tools and cloud-connected imaging platforms for remote diagnostics. - North America held the largest market share in 2025. - Asia-Pacific is projected to post the fastest growth over the forecast period. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

Between the lines: - The market thesis is less about one new device category and more about a broader shift toward safer screening tools that can fit into routine care. - The emphasis on AI, cloud sharing and portability suggests the next wave of competition may center on workflow integration as much as measurement accuracy. - The inclusion of a 2023 NHS referral example for brain MRI underscores a broader rise in demand for non-invasive diagnostics, even outside bone imaging.

What's next: - The report expects continued adoption of radiation-free imaging and point-of-care devices through 2030. - Market competition is likely to follow demand for AI-enabled diagnostics and remote imaging workflows. - The 2026 edition of the report adds market attractiveness scoring, TAM analysis, company scoring matrices, Excel-based forecasting dashboards, hotspots infographics and updated trend analysis.